In a murine model of HCC, Liu et al. demonstrated that the combination of a VEGFR-targeting peptide-drug conjugate with an anti-PD-1 mAb led to significant tumor growth inhibition and prolonged murine survival [149]. The gene discussed is PDCD1; the disease is neoplasm.